All News

Healthcare organizations can lower their risk of drug diversion by strengthening staffing, employee training, and technology.

Due to a global demand, treatments such as Adderall and Ritalin have been in short supply for the management of attention-deficit hyperactivity disorder.

Incidence rates have grown for leptomeningeal metastasis, a rapidly progressing and fatal complication of several cancers.

Ongoing phase 1 dose-escalation trial of KO-2806 (FIT-001) for the treatment of patients with KRASG12C-mutated non-small cell lung cancer expected to begin dosing patients in combination with adagrasib by mid-2024.

The newly approved Alinity m high risk human papillomavirus (HPV) assay is indicated to detect HPV and for use in routine cervical cancer screening per professional medical guidelines.

Inpefa to be added on pharmacy benefit manager’s basic and high-performance formularies for commercially insured patients.

Phathom Pharmaceuticals announced that it anticipates vonoprazan (Voquenza) to be commercially available by December 2023.

SLS009 is a novel CDK9 inhibitor under investigation for the treatment of relapsed/refractory peripheral T-cell lymphomas.

Exagamglogene autotemcel (exa-cel) has shown the potential to be a landmark therapy in preventing episodes of excruciating pain among patients with sickle cell disease.

Abatacept is indicated across multiple inflammatory conditions, including for the treatment of adult patients with moderately to severely active rheumatoid arthritis, pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis, and active juvenile psoriatic arthritis.

The FDA granted Wezlana with interchangeable designation after clinical trials found no clinically significant differences in safety and efficacy for the indicated conditions across multiple inflammatory diseases.

Furmonertinib is in development for the treatment of advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations.

The Alliance for mRNA Medicines is the first and only scientific and policy organization singularly focused on advancing and advocating for global mRNA innovation.

The approval of pembrolizumab (Keytruda; Merck) combined with gemcitabine and cisplatin for the treatment locally advanced unresectable or metastatic biliary tract cancer is the sixth sixth indication for the anti-PD-1 therapy for gastrointestinal cancers.

Collaboration to focus on enhancing physician engagement in clinical trials and cancer research.

The system was used by doctors at the Cleveland Clinic.

Collaboration to focus on advancing mRNA-based oncology therapeutics.

The EluNIR-PERL drug-eluting stent is used for the treatment of coronary artery disease.

Company’s new leader previously served in the same role at OnQuality Pharmaceuticals.

Executive previously served as chief financial officer of Moderna, Amgen, and 3M.

KYV-101 designed as a CD19 CAR T-cell therapy.

Sapio chemistry solution unifies small-molecule and large-molecule discovery workflows on a single platform.

GC1126A is designed to treat the rare blood disorder.

Kalinovich previously worked at Wabtec as a corporate vice president.

The gastric/gastroesophageal cancer treatment is produced by Transcenta.

Exec joins the organization with decades of biopharma experience.

The company announced that it is fully funded beyond clinical Phase IIb ALS results.

The injector is designed for at-home or in-clinic use.